{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:11:26Z","timestamp":1792127486506,"version":"4.4.0"},"reference-count":153,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.leukres.2011.05.006","type":"journal-article","created":{"date-parts":[[2011,6,19]],"date-time":"2011-06-19T15:49:34Z","timestamp":1308498574000},"page":"1143-1152","source":"Crossref","is-referenced-by-count":102,"title":["Tyrosine kinase inhibitors in the treatment of systemic mastocytosis"],"prefix":"10.1016","volume":"35","author":[{"given":"Celalettin","family":"Ustun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"DeRemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.05.006_bib0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0010","series-title":"World Health Organization (WHO) Classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues","first-page":"54","article-title":"Mastocytosis (Mast cell disease)","author":"Horny","year":"2008"},{"key":"10.1016\/j.leukres.2011.05.006_bib0015","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0025","first-page":"169","article-title":"How I treat patients with advanced systemic mastocytosis. Blood 2010, 6, Robyn J, Metcalfe DD. Systemic mastocytosis","volume":"89","author":"Valent","year":"2006","journal-title":"Adv Immunol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0065-2776(05)89005-4","article-title":"Systemic mastocytosis","volume":"89","author":"Robyn","year":"2006","journal-title":"Adv Immunol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ajh.20211","article-title":"Management of patients with systemic mastocytosis: review of M.D. Anderson Cancer Center experience","volume":"77","author":"Hennessy","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anai.2009.11.006","article-title":"Current approaches to the diagnosis and treatment of systemic mastocytosis","volume":"104","author":"Bains","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0045","first-page":"29","article-title":"Systemic mastocytosis: classification, pathogenesis, diagnosis, and treatment","volume":"83","author":"Bunimovich","year":"2009","journal-title":"Cutis"},{"key":"10.1016\/j.leukres.2011.05.006_bib0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MOH.0b013e3283366c59","article-title":"Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature","volume":"17","author":"Pardanani","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0055","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1309\/AJCPPXHMN5CJOXHZ","article-title":"Mastocytosis: an unusual clonal disorder of bone marrow-derived hematopoietic progenitor cells","volume":"132","author":"Horny","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0060","first-page":"399","article-title":"Systemic mastocytosis","volume":"142","author":"Valent","year":"2008","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000101711","article-title":"Mastocytosis: state of the art","volume":"74","author":"Horny","year":"2007","journal-title":"Pathobiology"},{"key":"10.1016\/j.leukres.2011.05.006_bib0070","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.beha.2005.07.010","article-title":"Pathogenesis, clinical features, and treatment advances in mastocytosis","volume":"19","author":"Pardanani","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2011.05.006_bib0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000085563","article-title":"Clonality and molecular pathogenesis of mastocytosis","volume":"114","author":"Akin","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0085","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1007\/s00018-004-4273-y","article-title":"Kit as a human oncogenic tyrosine kinase","volume":"61","author":"Kitamura","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.leukres.2011.05.006_bib0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jlb.67.2.135","article-title":"c-Kit and c-kit mutations in mastocytosis and other hematological diseases","volume":"67","author":"Boissan","year":"2000","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0095","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1007\/s00018-004-4189-6","article-title":"Signal transduction via the stem cell factor receptor\/c-kit","volume":"61","author":"Ronnstrand","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.leukres.2011.05.006_bib0100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/path.1711770207","article-title":"Expression of the c-kit gene product in normal and neoplastic mast cells but not in neoplastic basophil\/mast cell precursors from chronic myelogenous leukaemia","volume":"177","author":"Fukuda","year":"1995","journal-title":"J Pathol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.pai.0000173054.83414.22","article-title":"KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation","volume":"13","author":"Miettinen","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1095\/biolreprod52.1.8","article-title":"Expression of c-kit receptor and its autophosphorylation in immature rat type A spermatogonia","volume":"52","author":"Dym","year":"1995","journal-title":"Biol Reprod"},{"key":"10.1016\/j.leukres.2011.05.006_bib0115","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0960-9822(98)70302-1","article-title":"The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136","volume":"8","author":"Blume-Jensen","year":"1998","journal-title":"Curr Biol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0092-8674(03)01077-8","article-title":"Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems","volume":"116","author":"Pawson","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2011.05.006_bib0125","doi-asserted-by":"crossref","first-page":"31461","DOI":"10.1074\/jbc.C300186200","article-title":"Structure of a c-kit product complex reveals the basis for kinase transactivation","volume":"278","author":"Mol","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2011.05.006_bib0130","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.cellsig.2009.06.002","article-title":"Oncogenic signaling from the hematopoietic growth factor receptors c-kit and Flt3","volume":"21","author":"Masson","year":"2009","journal-title":"Cell Signal"},{"key":"10.1016\/j.leukres.2011.05.006_bib0135","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1002\/j.1460-2075.1987.tb02655.x","article-title":"Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand","volume":"6","author":"Yarden","year":"1987","journal-title":"EMBO J"},{"key":"10.1016\/j.leukres.2011.05.006_bib0140","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/j.1460-2075.1988.tb02907.x","article-title":"Primary structure of c-kit: relationship with the CSF-1\/PDGF receptor kinase family\u2014oncogenic activation of v-kit involves deletion of extracellular domain and C terminus","volume":"7","author":"Qiu","year":"1988","journal-title":"EMBO J"},{"key":"10.1016\/j.leukres.2011.05.006_bib0145","first-page":"2221","article-title":"KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells","volume":"8","author":"Zakut","year":"1993","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2011.05.006_bib0150","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1074\/jbc.272.10.6311","article-title":"Kit receptor dimerization is driven by bivalent binding of stem cell factor","volume":"272","author":"Lemmon","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2011.05.006_bib0155","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1357-2725(99)00078-3","article-title":"Early signaling pathways activated by c-Kit in hematopoietic cells","volume":"31","author":"Linnekin","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0160","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1096\/fasebj.6.8.1317309","article-title":"Signal transduction from cell surface to nucleus in development and disease","volume":"6","author":"Karin","year":"1992","journal-title":"FASEB J"},{"key":"10.1016\/j.leukres.2011.05.006_bib0165","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood.V80.12.3009.3009","article-title":"Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells","volume":"80","author":"Irani","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0170","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.V80.9.2237.2237","article-title":"Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor\/kit-ligand in long-term culture","volume":"80","author":"Valent","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0175","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4049\/jimmunol.148.3.772","article-title":"Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells","volume":"148","author":"Kirshenbaum","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0180","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1073\/pnas.90.2.735","article-title":"Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand","volume":"90","author":"Mitsui","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2011.05.006_bib0185","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2002-11-3490","article-title":"Stat5 expression is critical for mast cell development and survival","volume":"102","author":"Shelburne","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0190","first-page":"321","article-title":"The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis","volume":"144","author":"Iemura","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0195","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1073\/pnas.95.12.6930","article-title":"T1\/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function","volume":"95","author":"Lohning","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2011.05.006_bib0200","doi-asserted-by":"crossref","first-page":"26369","DOI":"10.1074\/jbc.M704916200","article-title":"Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation","volume":"282","author":"Hayakawa","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2011.05.006_bib0205","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.imlet.2007.08.007","article-title":"G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation","volume":"113","author":"Kuehn","year":"2007","journal-title":"Immunol Lett"},{"key":"10.1016\/j.leukres.2011.05.006_bib0210","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood-2009-10-247411","article-title":"The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells","volume":"115","author":"Drube","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0215","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.leukres.2011.05.006_bib0220","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/hupa.2002.129199","article-title":"Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis","volume":"33","author":"Naeem","year":"2002","journal-title":"Hum Pathol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4652(199707)172:1<1::AID-JCP1>3.0.CO;2-S","article-title":"Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1","volume":"172","author":"Bellone","year":"1997","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0230","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2141.1995.tb05364.x","article-title":"c-kit point mutation of extracellular domain in patients with myeloproliferative disorders","volume":"91","author":"Nakata","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0235","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood.V84.10.3465.3465","article-title":"Expression of stem cell factor and c-kit in human neuroblastoma, The Children's Cancer Group","volume":"84","author":"Cohen","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0240","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ijc.2910520508","article-title":"Breast cancer is associated with loss of the c-kit oncogene product","volume":"52","author":"Natali","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2011.05.006_bib0245","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2174\/156800907781386614","article-title":"Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders","volume":"7","author":"Patnaik","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.leukres.2011.05.006_bib0250","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood.V87.8.3117.bloodjournal8783117","article-title":"A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells","volume":"87","author":"Piao","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0255","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood.V83.9.2619.2619","article-title":"Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation","volume":"83","author":"Tsujimura","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0260","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2011.05.006_bib0265","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.V85.3.790.bloodjournal853790","article-title":"Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines","volume":"85","author":"Kitayama","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0270","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000236870","article-title":"Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3","volume":"106","author":"Tsujimura","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0275","first-page":"189","article-title":"Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line","volume":"148","author":"Hashimoto","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0280","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2011.05.006_bib0285","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.leukres.2011.05.006_bib0290","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0295","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0300","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1365-2141.1997.d01-2042.x","article-title":"A new c-kit mutation in a case of aggressive mast cell disease","volume":"96","author":"Pignon","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0305","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2011.05.006_bib0310","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ajh.10322","article-title":"Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations","volume":"73","author":"Pullarkat","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0315","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9440(10)63870-9","article-title":"One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes","volume":"162","author":"Sotlar","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0320","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/labinvest.3700524","article-title":"Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation","volume":"87","author":"Nakagomi","year":"2007","journal-title":"Lab Invest"},{"key":"10.1016\/j.leukres.2011.05.006_bib0325","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1523-1747.1998.00414.x","article-title":"Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior","volume":"111","author":"Buttner","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0330","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0335","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/10428190802140865","article-title":"The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells","volume":"49","author":"Ozer","year":"2008","journal-title":"Leuk Lymp"},{"key":"10.1016\/j.leukres.2011.05.006_bib0340","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1136\/jmg.2003.015156","article-title":"A germline mutation in KIT in familial diffuse cutaneous mastocytosis","volume":"41","author":"Tang","year":"2004","journal-title":"J Med Genet"},{"key":"10.1016\/j.leukres.2011.05.006_bib0345","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0350","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.gastro.2005.06.060","article-title":"Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis","volume":"129","author":"Hartmann","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.leukres.2011.05.006_bib0355","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2008-03-147785","article-title":"Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation","volume":"112","author":"Hoffmann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0360","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1525-1578(10)60552-1","article-title":"c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation","volume":"7","author":"Yanagihori","year":"2005","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.leukres.2011.05.006_bib0365","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000096907","article-title":"C-kit Asp-816-Val mutation analysis in patients with mastocytosis","volume":"214","author":"Verzijl","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.leukres.2011.05.006_bib0370","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.10.020","article-title":"Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes","volume":"125","author":"Teodosio","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0375","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","article-title":"Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene","volume":"100","author":"Yavuz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0380","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0301-472X(99)00145-9","article-title":"Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis","volume":"28","author":"Akin","year":"2000","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0385","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.2353\/ajpath.2009.080953","article-title":"Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V","volume":"175","author":"Baumgartner","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0390","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2002-11-3490","article-title":"Stat5 expression is critical for mast cell development and survival","volume":"102","author":"Shelburne","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0395","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0161-5890(02)00061-5","article-title":"Stat5: an essential regulator of mast cell biology","volume":"38","author":"Shelburne","year":"2002","journal-title":"Mol Immunol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0400","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","article-title":"Oncogenic kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade","volume":"112","author":"Harir","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0405","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood.V97.11.3559","article-title":"Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells","volume":"97","author":"Ning","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0410","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1074\/jbc.M110.182642","article-title":"Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells","volume":"286","author":"Chaix","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2011.05.006_bib0415","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011083031272","article-title":"Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL","volume":"21","author":"Mekori","year":"2001","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0420","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/(SICI)1096-8652(199903)60:3<191::AID-AJH4>3.0.CO;2-Y","article-title":"Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia","volume":"60","author":"Cervero","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0425","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2008-08-175190","article-title":"Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs","volume":"114","author":"Aichberger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0430","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood-2004-12-4792","article-title":"Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim","volume":"106","author":"Moller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0435","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.V98.5.1365","article-title":"Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant","volume":"98","author":"Chian","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0440","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1002\/j.1460-2075.1993.tb06104.x","article-title":"Increased Kit\/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C","volume":"12","author":"Blume-Jensen","year":"1993","journal-title":"EMBO J"},{"key":"10.1016\/j.leukres.2011.05.006_bib0445","doi-asserted-by":"crossref","first-page":"14192","DOI":"10.1074\/jbc.270.23.14192","article-title":"Identification of the major phosphorylation sites for protein kinase C in kit\/stem cell factor receptor in vitro and in intact cells","volume":"270","author":"Blume-Jensen","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2011.05.006_bib0450","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.beha.2009.06.001","article-title":"Management of drug toxicities in chronic myeloid leukaemia","volume":"22","author":"Mauro","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0455","unstructured":"Gleevec dosing and administration. http:\/\/www.gleevec.com\/health-care-professional\/dosing-for-gleevec.jsp."},{"key":"10.1016\/j.leukres.2011.05.006_bib0460","unstructured":"Dasatinib dosing. http:\/\/www.sprycel.com\/hcp\/dosing.aspx."},{"key":"10.1016\/j.leukres.2011.05.006_bib0465","unstructured":"Nilotinib. http:\/\/www.us.tasigna.com\/health-care-professional."},{"key":"10.1016\/j.leukres.2011.05.006_bib0470","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ijc.11025","article-title":"Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors","volume":"105","author":"Chen","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2011.05.006_bib0475","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0480","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0485","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2011.05.006_bib0490","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2011.05.006_bib0495","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0889-8588(05)70302-6","article-title":"New approaches to therapy for mastocytosis. A case for treatment with kit kinase inhibitors","volume":"14","author":"Longley","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.leukres.2011.05.006_bib0500","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0505","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12185-008-0166-4","article-title":"Advanced mast cell disease: an Italian hematological multicenter experience","volume":"88","author":"Pagano","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0510","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2011.05.006_bib0515","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0520","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2011.05.006_bib0525","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-07-4575","article-title":"Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases","volume":"14","author":"Heinrich","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0530","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","article-title":"The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management","volume":"103","author":"Gotlib","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0535","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0540","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2011.05.006_bib0545","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000312134","article-title":"FIP1L1\/PDGFR alpha-associated systemic mastocytosis","volume":"152","author":"Yamada","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0550","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3324\/haematol.11836","article-title":"Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion","volume":"93","author":"Lahortiga","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.05.006_bib0555","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/PPO.0b013e31815a9618","article-title":"Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease","volume":"13","author":"Pardanani","year":"2007","journal-title":"Cancer J"},{"key":"10.1016\/j.leukres.2011.05.006_bib0560","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.leukres.2005.11.014","article-title":"Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1\/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib","volume":"30","author":"Florian","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0565","series-title":"World Health Organization (WHO) Classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues","first-page":"68","article-title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1","author":"Bain","year":"2008"},{"key":"10.1016\/j.leukres.2011.05.006_bib0570","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0575","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0580","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3324\/haematol.12793","article-title":"Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC\/ABL inhibitor dasatinib","volume":"93","author":"Fabarius","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.05.006_bib0585","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0590","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.11339","article-title":"Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT","volume":"92","author":"Gleixner","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2011.05.006_bib0595","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2362.2008.02036.x","article-title":"Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis","volume":"38","author":"Aichberger","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.leukres.2011.05.006_bib0600","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0605","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0610","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","article-title":"Dasatinib therapy for systemic mastocytosis: four cases","volume":"80","author":"Purtill","year":"2008","journal-title":"Eur J Haematol"},{"issue":"258b","key":"10.1016\/j.leukres.2011.05.006_bib0615","article-title":"Systemic mastocytosis with c-KITD816V mutation treated with dasatinib","volume":"110","author":"Benz","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0620","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.leukres.2008.09.027","article-title":"Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V","volume":"33","author":"Ustun","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0625","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood-2007-08-104372","article-title":"The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils","volume":"111","author":"Kneidinger","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0630","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0635","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","article-title":"Profound inhibition of antigen-specific T-cell effector functions by dasatinib","volume":"14","author":"Weichsel","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0640","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","article-title":"Immunosuppression and atypical infections in CML patients treated with dasatinib at 140mg daily","volume":"39","author":"Sillaber","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.leukres.2011.05.006_bib0645","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patient with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0650","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0655","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0660","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"Deremer","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.leukres.2011.05.006_bib0665","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/CMAR.S11948","article-title":"Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia","volume":"3","author":"Deremer","year":"2011","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0670","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/sj.leu.2403887","article-title":"The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107","volume":"19","author":"von Bubnoff","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2011.05.006_bib0675","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.leukres.2006.04.005","article-title":"Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit","volume":"30","author":"Verstovsek","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0680","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2703.2703","article-title":"A phase II study of nilotinib, a novel inhibitor of c-Kit, PDGFR, and Bcr-Abl, administered to patients with systemic mastocytosis","volume":"108","author":"Hochhaus","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4889(98)00178-5","article-title":"Signal preception and transduction: the role protein kinases","volume":"1449","author":"Schenk","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.leukres.2011.05.006_bib0690","first-page":"181","article-title":"The role of protein kinase C in G1 and G2\/M phases of the cell cycle (review)","volume":"12","author":"Fishman","year":"1998","journal-title":"Int J Oncol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0695","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ijc.2910430519","article-title":"A derivative of staurosporine (CGP 41251) shows selectivity of protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity","volume":"43","author":"Meyer","year":"1989","journal-title":"Int J Cancer"},{"key":"10.1016\/j.leukres.2011.05.006_bib0700","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.2001.19.5.1485","article-title":"Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C","volume":"19","author":"Propper","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0705","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","article-title":"Plasma inhibitory activity (PIA): a pharmacodynamid assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors","volume":"108","author":"Levis","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0710","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0715","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.leukres.2011.05.006_bib0720","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.316.316","article-title":"KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial","volume":"116","author":"Gotlib","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0725","doi-asserted-by":"crossref","first-page":"e7258","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2011.05.006_bib0730","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","article-title":"Masitinib is safe and effective for the treatment of canine mast cell tumors","volume":"22","author":"Hahn","year":"2008","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.leukres.2011.05.006_bib0735","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2460\/ajvr.71.11.1354","article-title":"Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors","volume":"71","author":"Hahn","year":"2010","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.leukres.2011.05.006_bib0740","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/blood-2004-06-2189","article-title":"Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970","volume":"104","author":"Corbin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0745","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1038\/sj.onc.1210159","article-title":"Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate","volume":"26","author":"Kosmider","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2011.05.006_bib0750","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2006-04-013805","article-title":"EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation","volume":"109","author":"Pan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0755","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.exphem.2010.05.004","article-title":"KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406)","volume":"38","author":"Peter","year":"2010","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2011.05.006_bib0760","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2004-12-4771","article-title":"In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit","volume":"106","author":"Corbin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.05.006_bib0765","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1158\/0008-5472.CAN-08-0034","article-title":"Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells","volume":"69","author":"Faderl","year":"2009","journal-title":"Cancer Res"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611002232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212611002232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T14:01:34Z","timestamp":1686146494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212611002232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":153,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0145212611002232"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.05.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}